Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published November 25, 2022 | Published + Supplemental Material
Journal Article Open

Expedient Synthesis of a Library of Heparan Sulfate‐Like "Head-to-Tail" Linked Multimers for Structure and Activity Relationship Studies

Abstract

Heparan sulfate (HS) plays important roles in many biological processes. The inherent complexity of naturally existing HS has severely hindered the thorough understanding of their structure-activity relationship. To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module. Combinatorial syntheses of 27 HS-like pseudo-hexasaccharides were achieved. This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages. The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.

Additional Information

© 2022 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. We are grateful for financial supports from the National Institute of General Medical Sciences, NIH (R01GM072667, U01GM116262, and R44GM134738 to X.H., J.L. and L.H.; S10OD028523 to F.Z. and R.L.), National Institute of Environmental Health Sciences (R01ES030695 to J.J.B.), the National Science Foundation (DMR-1933525 to F.Z., J.L. and R.L.), and Michigan State University for financial support of our work. We would like to thank Prof. Erika Lisabeth (Assay Development and Drug Discovery Core, MSU) for her expert help on SPR data processing. Data Availability Statement. The data that support the findings of this study are available in the Supporting Information of this article. Conflict of interest. J.L. is a founder and chief scientific officer for Glycan Therapeutics. He has equity in the company and serves as a paid consultant.

Attached Files

Published - ANIE-61-0.pdf

Supplemental Material - ANIE-61-0-s001.pdf

Files

ANIE-61-0-s001.pdf
Files (27.5 MB)
Name Size Download all
md5:90fe03bae4d6f9e07615150a370365c4
19.8 MB Preview Download
md5:347deaafd1564e497fb4a0ed98449d7b
7.7 MB Preview Download

Additional details

Created:
September 15, 2023
Modified:
October 23, 2023